FDA grants BOLD-100 Orphan Drug Designation in the treatment of gastric cancer

This first-in-class ruthenium-based small molecule therapeutic is currently being investigated in Phase 1b trial for the treatment of advanced gastric, pancreatic, colorectal and bile duct cancers. Data shows potential improved outcomes for both liquid and solid tumours.

Source:

Biospace Inc.